½ÃÀ庸°í¼­
»óǰÄÚµå
1671963

¼¶À¯±ÙÀ°Åë Ä¡·á ½ÃÀå : À¯Åë ä³Îº°, Áö¿ªº°

Fibromyalgia Treatment Market,, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¼¶À¯±ÙÀ°Åë Ä¡·á ½ÃÀåÀº 2025³â¿¡´Â 31¾ï 8,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 40¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 3.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ 2024 2025³â ½ÃÀå ±Ô¸ð 31¾ï 8,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR : 3.50% 2032³â °¡Ä¡ ¿¹Ãø 40¾ï 5,000¸¸ ´Þ·¯
µµÇ¥. ¼¶À¯±ÙÀ°Åë Ä¡·á ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº°
Fibromyalgia Treatment Market-IMG1

¼¶À¯±ÙÀ°ÅëÀº ±ÙÀ°, Àδë, ÈûÁÙÀÇ ¸¸¼ºÀûÀÌ°í ±¤¹üÀ§ÇÑ ÅëÁõ°ú ¾ÐÅëÀ» Ư¡À¸·Î ÇÏ´Â ÁúȯÀÔ´Ï´Ù. Á¾Á¾ ÇÇ·Î, ¼ö¸éÀå¾Ö, ±â¾ï·Â Àå¾Ö, ±âºÐ Àå¾Ö¸¦ µ¿¹ÝÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¼¶À¯±ÙÀ°ÅëÀÇ Á¤È®ÇÑ ¿øÀÎÀº ¾ÆÁ÷ ¹àÇôÁöÁö ¾Ê¾ÒÁö¸¸, ³úÀÇ ½Å°æ È­ÇÐÀû ºÒ±ÕÇüÀÌ ¿øÀÎÀ¸·Î ¿©°ÜÁö°í ÀÖ½À´Ï´Ù. ±× Áõ»óÀº °íÅë¹Þ´Â »ç¶÷µéÀÇ »îÀÇ Áú¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÇöÀç·Î¼­´Â ¼¶À¯±ÙÀ°ÅëÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀº ¾øÁö¸¸, Ä¡·á´Â Áõ»óÀ» °ü¸®Çϰí ÀÏ»ó»ýȰÀÇ ±â´ÉÀ» °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÀϹÝÀûÀÎ Ä¡·á¹ýÀ¸·Î´Â ¾à¼öó¸®, »ýȰ½À°ü °³¼±, ´ëü¿ä¹ý, ÀÎÁöÇൿġ·á µîÀÌ ÀÖ½À´Ï´Ù. ¼¼°è ¼¶À¯±ÙÀ°Åë Ä¡·á ½ÃÀåÀº Áø´ÜÀ² Áõ°¡¿Í Áõ»ó¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Å« ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è ¼¶À¯±ÙÀ°Åë Ä¡·á ½ÃÀåÀº Àü ¼¼°è ¼¶À¯±ÙÀ°Åë À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¼¶À¯±ÙÀ°ÅëÀº Àü ¼¼°è Àα¸ÀÇ ¾à 2-8%°¡ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶ÇÇÑ ¼¶À¯±ÙÀ°Åë Ä¡·á¸¦ À§ÇÑ »õ·Î¿î ¾à¹° Á¦Á¦ÀÇ ½ÂÀÎ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº Ä¡·áºñ¿ë°ú Ä¡·á¹ýÀÌ È®¸³µÇÁö ¾ÊÀº Á¡ÀÌ ½ÃÀå ÀáÀç·ÂÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ»çµéÀÇ ÀÎ½Ä ºÎÁ·µµ ¹®Á¦Á¡À¸·Î ÁöÀûµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå °³¹ßÀÚµéÀº ¼¶À¯±ÙÀ°Åë Ä¡·á¸¦ À§ÇÑ »õ·Î¿î Á¦Á¦¸¦ °³¹ßÇÏ¿© Àú·ÅÇÑ °¡°ÝÀ¸·Î Ä¡·á ¿É¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ ¾ò°í ÀÖ½À´Ï´Ù. »ý¹°Á¦Á¦ÀÇ Ã¤Åà Áõ°¡´Â »õ·Î¿î ¼ºÀåÀÇ ±æÀ» ¿­¾îÁÙ °ÍÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ¼¼°èÀÇ ¼¶À¯±ÙÀ°Åë Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(BN$)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ¼¶À¯±ÙÀ°Åë Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ¾÷ü¸¦ ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è ¼¶À¯±ÙÀ°Åë Ä¡·á ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¼¶À¯±ÙÀ°Åë Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • ¸®Æ÷Æ® ¼³¸í
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • °³¿ä
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
  • ¿µÇ⠺м®
  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • ƯÇã ¼Ò¼Û
  • »óȯ
  • ƯÇã »óȲ(ANDA/NDA ÀÎÅÚ¸®Àü½º)
  • PEST ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®

Á¦4Àå ¼¼°èÀÇ ¼¶À¯±ÙÀ°Åë Ä¡·á ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎ ±¸»ó
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ¼¶À¯±ÙÀ°Åë Ä¡·á ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • Ç׿ì¿ïÁ¦
  • Ç×°£Áú¾à
  • ±ÙÀÌ¿ÏÁ¦
  • ÁøÅëÁ¦
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ ¼¶À¯±ÙÀ°Åë Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦7Àå ¼¼°èÀÇ ¼¶À¯±ÙÀ°Åë Ä¡·á ½ÃÀå, Áö¿ªº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï ±¸µµ

  • È÷Æ®¸Ê ºÐ¼®
  • ±â¾÷ °³¿ä
    • Eli Lilly and Company
    • Pfizer, Inc.
    • Novartis AG
    • Allergan plc
    • Sun Pharmaceutical Industries Ltd.
    • Aptinyx, Inc.
    • Prismic Pharmaceuticals, Inc.
    • Innovative Med Concepts, Inc.
    • Intec Pharma Ltd
    • Astellas Pharma Inc.
    • Johnson &Johnson
    • GSK
    • AstraZeneca plc
    • Bristol Myers Squibb
    • Viatris
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Sanofi

Á¦9Àå ¾Ö³Î¸®½ºÆ®ÀÇ ½ÃÁ¡

Á¦10Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
KSA 25.04.14

Global Fibromyalgia Treatment Market is estimated to be valued at USD 3.18 Bn in 2025 and is expected to reach USD 4.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.5% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 3.18 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 3.50% 2032 Value Projection: USD 4.05 Bn
Figure. Fibromyalgia Treatment Market Share (%), By Region 2025
Fibromyalgia Treatment Market - IMG1

Fibromyalgia is a disorder characterized by chronic widespread pain and tenderness in the muscles, ligaments and tendons. It is often accompanied by fatigue, sleep issues, memory and mood issues. The exact cause of fibromyalgia is still unknown but is believed to be due to neurochemical imbalance in the brain. The symptoms negatively impact quality of life of those suffering from it. Currently there is no cure for fibromyalgia but the treatment aims to manage symptoms and improve day to day functioning. Some of the common treatment options include medications, lifestyle changes, alternate therapies, cognitive behavior therapy etc. The global fibromyalgia treatment market is expected to witness significant growth due to the increasing diagnosis rates and growing awareness about the condition.

Market Dynamics:

The global fibromyalgia treatment market is driven by the rising prevalence of fibromyalgia worldwide. As per estimates, fibromyalgia affects about 2-8% of the global population. Moreover, increasing approval of new drug formulations for fibromyalgia treatment is also boosting the market growth. However, high cost of treatment therapies and lack of cure hinders the market potential. Lack of awareness among physicians also poses a challenge. The market players have opportunities to develop novel drug formulations for fibromyalgia cure and offer treatment options at affordable prices. Increasing adoption of biologics also opens new growth avenues.

Key Features of the Study:

  • This report provides in-depth analysis of the global fibromyalgia treatment market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global fibromyalgia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study includes Eli Lilly and Company, Pfizer Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx Inc., Prismic Pharmaceuticals Inc., Innovative Med Concepts Inc., Intec Pharma Ltd., Astellas Pharma Inc., Johnson & Johnson, GSK, AstraZeneca plc, Bristol Myers Squibb, Viatris, Takeda Pharmaceutical Company Limited, Amgen Inc., and Sanofi.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global fibromyalgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibromyalgia treatment market.

Market Segmentation

  • Drug Class:
    • Antidepressants
    • Antiepileptics
    • Muscle Relaxants
    • Analgesics
    • Others
  • Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Eli Lilly and Company
    • Pfizer Inc.
    • Novartis AG
    • Allergan plc
    • Sun Pharmaceutical Industries Ltd.
    • Aptinyx Inc.
    • Prismic Pharmaceuticals Inc.
    • Innovative Med Concepts Inc.
    • Intec Pharma Ltd.
    • Astellas Pharma Inc.
    • Johnson & Johnson
    • GSK
    • AstraZeneca plc
    • Bristol Myers Squibb
    • Viatris
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Sanofi

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Patent Litigations
  • Reimbursement
  • Patent Landscape (ANDA/NDA Intelligence)
  • PEST Analysis
  • Porter's Analysis

4. Global Fibromyalgia Treatment Market- Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Fibromyalgia Treatment Market, By Drug Class, 2020 - 2032, (USD BN)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Antidepressants
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
    • Segment Trends
  • Antiepileptics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
    • Segment Trends
  • Muscle Relaxants
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
  • Analgesics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

6. Global Fibromyalgia Treatment Market, By Distribution Channel, 2020 - 2032, (USD BN)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

7. Global Fibromyalgia Treatment Market, By Region, 2020 - 2032, (USD BN)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Regions, 2020-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD BN)
      • North Africa
      • Central Africa
      • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Eli Lilly and Company
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer, Inc.
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Market Strategies
    • Allergan plc
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Market Strategies
    • Sun Pharmaceutical Industries Ltd.
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Market Strategies
    • Aptinyx, Inc.
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Market Strategies
    • Prismic Pharmaceuticals, Inc.
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Market Strategies
    • Innovative Med Concepts, Inc.
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Market Strategies
    • Intec Pharma Ltd
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Market Strategies
    • Astellas Pharma Inc.
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Market Strategies
    • Johnson & Johnson
      • Company Overview
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Market Strategies
    • GSK
    • AstraZeneca plc
    • Bristol Myers Squibb
    • Viatris
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Sanofi

9. Analyst View

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

10. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦